- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 23.09. | OSR Holdings, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.09. | OSR Holdings verstößt gegen NASDAQ-Mindestkursanforderung | - | Investing.com Deutsch | ||
| 09.09. | OSR Holdings receives Nasdaq notice for minimum bid price non-compliance | 1 | Seeking Alpha | ||
| 09.09. | OSR Holdings receives Nasdaq minimum bid price deficiency notice | 2 | Investing.com | ||
| 09.09. | OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity | 84 | PR Newswire | BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (Nasdaq: OSRH) today announced that on September 5, 2025, it received a written notification from... ► Artikel lesen | |
| 09.09. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 20.08. | OSR Holdings ändert Vereinbarungen mit White Lion Capital und beruft Hauptversammlung ein | 2 | Investing.com Deutsch | ||
| OSR HOLDINGS Aktie jetzt für 0€ handeln | |||||
| 20.08. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.08. | OSR Holdings, Inc. - 10-Q, Quarterly Report | 3 | SEC Filings | ||
| 06.08. | OSR Holdings, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.07. | OSR Holdings informiert über Eigenkapitalfinanzierung und Aktienausgabe | 2 | Investing.com Deutsch | ||
| 31.07. | OSR Holdings updates on equity financing, shares issued under ELOC | 1 | Investing.com | ||
| 30.07. | OSR Holdings advances acquisition of Korean glucose monitoring firm | 1 | Investing.com | ||
| 30.07. | OSR Holdings Inc.: OSR Holdings Provides Strategic Update on Woori IO Term Sheet and Share Exchange Structure | 162 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 30, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 25.07. | OSR Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 25.07. | Gambling Commission responds to OSR recommendations following GSGB review | 2 | iGaming Business | ||
| 24.07. | OSR Holdings signs term sheet to acquire noninvasive glucose tech firm | 1 | Investing.com | ||
| 24.07. | OSR Holdings enters term sheet to acquire Woori IO | 1 | Seeking Alpha | ||
| 24.07. | OSR Holdings Inc.: OSR Holdings Enters into Term Sheet to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring Technology | 122 | PR Newswire | BELLEVUE, Wash. and SEOUL, South Korea, July 24, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company advancing biomedical and... ► Artikel lesen | |
| 15.07. | OSR appoints Andreas Niethammer as Chief Medical Officer of Vaximm AG | 1 | Seeking Alpha |
1 2 Weiter >>
38 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 40,470 | -1,56 % | Sysmex, QIAGEN Announce Exclusive Distribution Partnership For Diagnostic Products In Japan | TOKYO (dpa-AFX) - Sysmex Corporation (SSMXY.PK) and QIAGEN K.K., the Japanese subsidiary of QIAGEN N.V., announced on Wednesday that they have entered into a partnership for clinical diagnostic... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 20,050 | -3,19 % | Arcutis Biotherapeutics, Inc.: FDA Approves Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Atopic Dermatitis in Children Ages 2 to 5 | ZORYVE cream 0.05% provides rapid and effective relief of mild to moderate atopic dermatitis in children ages 2 to 5 and is safe and well toleratedOnce-daily, steroid-free cream can be used anywhere... ► Artikel lesen | |
| EVOTEC | 6,698 | -0,86 % | Evotec Aktie: Strohfeuer oder klappt es diesmal? | Die Evotec Aktie zeigt Stärke - aber diesmal auch für eine längere Zeit? Seit dem 26. September hat sich die TecDAX-notierte Biotech-Aktie von 5,882 Euro um mehr als einen Euro verteuert. Am gestrigen... ► Artikel lesen | |
| 89BIO | 14,800 | -0,34 % | Roche Launches Tender Offer To Acquire 89bio For $14.50/shr Plus CVR | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced that it has launched a tender offer to acquire all outstanding common shares of 89bio, Inc. (ETNB). The offer includes... ► Artikel lesen | |
| BIONTECH | 87,95 | +0,11 % | BioNTech Aktie zeigt Stärke: Es wird spannend! | Seit dem letzten 4investors.de-Chartcheck zur BioNTech Aktie hat sich einiges getan. Der Aktienkurs des Mainzer Biotech-Konzerns ist an der NASDAQ um rund 9 Dollar gestiegen, hat die 20- und 50-Tage-Linie... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,305 | -10,24 % | Recursion Pharmaceuticals (RXRX) Climbs 16% Ahead of AI Conference | ||
| BEAM THERAPEUTICS | 26,340 | -5,49 % | Jefferies stuft Beam Therapeutics auf "Buy": Kommende Katalysatoren im Fokus | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 10,290 | +9,70 % | Oppenheimer senkt Kursziel für Moonlake Immunotherapeutics nach durchwachsenen Studienergebnissen | ||
| MINERALYS THERAPEUTICS | 42,170 | +7,06 % | Mineralys Therapeutics: Aktie erreicht Rekordhoch von 41,11 USD | ||
| ARCELLX | 86,80 | -1,84 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| LENZ THERAPEUTICS | 38,740 | -16,24 % | Piper Sandler raises LENZ Therapeutics stock price target to $67 on VIZZ launch | ||
| APOGEE THERAPEUTICS | 52,45 | -1,43 % | Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $345 Million | SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for... ► Artikel lesen | |
| BICARA THERAPEUTICS | 17,780 | -2,58 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update | Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC Data from additional Phase 1/1b expansion cohorts evaluating... ► Artikel lesen | |
| COGENT BIOSCIENCES | 16,250 | +0,37 % | Cogent Biosciences, Inc.: Cogent Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WALTHAM, Mass. and BOULDER, Colo., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,320 | -5,87 % | UBS bestätigt Kaufempfehlung für Summit Therapeutics vor ESMO-Daten |
Das Unternehmen OSR HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -8,82 % bei einem Aktienkurs von 0,556 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HOLDINGS INC finden Sie auf Wallstreet Online.